Cooperative Agreement U01CA294209
Award Date
8/12/24
Completion Date
7/31/27
Dollars Obligated
$832K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Cooperative Agreement
Place of Performance
Worcester, MA 01655, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $877,856 Cooperative Agreement under the Cancer Biology Research (CFDA 93.396) program to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. to develop the Galaxy for Cancer (Galaxy-C) computational workbench. The goal is to create a platform that enables cancer researchers, especially those with limited computational skills, to more easily access, analyze, and extract insights from diverse cancer datasets and analysis tools....
This federal Cooperative Agreement award for $811,500.00 from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) supports research to bridge the gap between bioinformatics and mathematical modeling for patient-specific tumor modeling. The project aims to merge bioinformatics software for analyzing single-cell and spatial multi-omics data with an agent-based modeling framework to simulate cell interactions in virtual tumor environments. Key objectives include refining a cell...
The National Cancer Institute (NCI) awarded a $417,586 Project Grant (CFDA 93.396 - Cancer Biology Research) to The Broad Institute, Inc. to develop a "Platform for Multi-Modal Single Nucleus Spatial Genomics for Molecular Tumor Analysis." This 3-year project, commencing on August 1, 2024, aims to extend the institute's "Slide-Tags" single-cell spatial genomics technology to enable comprehensive profiling of human tumor samples. The project will integrate molecular, cellular,...
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $872,555 to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, MA over a five-year period from September 1, 2024 to August 31, 2029. The award aims to catalyze long-read cancer genome sequencing efforts through the development of informatic methods for the discovery and characterization of somatic genetic alterations in cancer genomes. Key objectives include improving...
The National Cancer Institute (NCI) awarded a $791,820 Cooperative Agreement under CFDA 93.396 - Cancer Biology Research to the University of California, San Diego (UCSD) to advance the METASPACE open-source software platform for spatial metabolomics in cancer research. The project aims to enhance METASPACE's utility and accelerate the adoption of spatial metabolomics, which provides unprecedented insights into the tumor microenvironment, cell-cell heterogeneity, and metabolic reprogramming in...
This $2,372,456 Project Grant awarded by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will support a collaborative research program led by Memorial Sloan Kettering Cancer Center focused on leveraging observational (real-world) data to advance precision oncology. The key products and services to be delivered include: Overcoming methodological barriers in the analysis of observational clinico-genomic data (Project 1) Addressing the role of genetic ancestry...
The National Cancer Institute (NCI) awarded a $455,111 Project Grant under CFDA 93.393 "Cancer Cause and Prevention Research" to the Sloan-Kettering Institute for Cancer Research in New York. The 2-year grant, awarded on September 5, 2023, will support research to "Leverage the Hidden Genome to Recover the Missing Heritability of Cancer." The project aims to 1) estimate additional heritability that can be explained by the "hidden genome" (regions of unknown...
The Project Grant award R35CA293978, provided by the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research), supports research to identify the mechanisms driving rapid evolution of cancer genomes. The $942,442 award to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, MA will fund investigations into two catastrophic mutational processes in cancer, chromothripsis and chromoplexy. The research aims to better understand the mechanisms of chromosome fragmentation, DNA...
The National Cancer Institute (NCI) awarded a $632,300 Project Grant under the Cancer Biology Research program (CFDA 93.396) to Carnegie Mellon University. The grant will fund the development of an integrated ultrahigh-throughput 3D volumetric super-resolution imaging system. This system will combine a multiscale fluorescence mesoscope with magnify expansion microscopy to enable rapid, large-area 3D imaging with exceptional subcellular detail. The goal is to study interactions between cancer and...
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $639,882 to the University of North Carolina at Chapel Hill to conduct research aimed at elucidating the molecular mechanisms underlying metastasis organ tropism in breast cancer. The project will utilize a comprehensive dataset of human primary and metastatic tumor samples, as well as genetically engineered mouse models, to identify the molecular determinants driving lung and...